ImmunoGen (IMGN) Reports a Q2 Loss; Comments on FY Outlook
Tweet Send to a Friend
ImmunoGen, Inc. (NASDAQ: IMGN) reports a Q2 loss of $0.23, 2 cents worse than the analyst estimate of ($0.21) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
